Who are Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bufomix-easyhaler-160-4-5-g-inhalation-dmdpi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI — Competitive Intelligence Brief

Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI (Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination of inhaled corticosteroid (ICS) and long-acting beta2-adrenergic agonist (LABA). Area: Immunology.

marketed Combination of inhaled corticosteroid (ICS) and long-acting beta2-adrenergic agonist (LABA) Glucocorticoid receptors and β2-adrenergic receptors Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI (Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI) — Orion Corporation, Orion Pharma. Bufomix® Easyhaler® combines an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) to reduce inflammation and bronchodilation in the airways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI TARGET	Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI	Orion Corporation, Orion Pharma	marketed	Combination of inhaled corticosteroid (ICS) and long-acting beta2-adrenergic agonist (LABA)	Glucocorticoid receptors and β2-adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination of inhaled corticosteroid (ICS) and long-acting beta2-adrenergic agonist (LABA) class)

Orion Corporation, Orion Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI — Competitive Intelligence Brief. https://druglandscape.com/ci/bufomix-easyhaler-160-4-5-g-inhalation-dmdpi. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab